BRIEF-Jounce Says Termination Of Proposed Business Combination With Redx Pharma PLC

Reuters2023-04-03

April 3 (Reuters) - Jounce Therapeutics Inc :

* TERMINATION OF PROPOSED BUSINESS COMBINATION OF JOUNCE THERAPEUTICS, INC. AND REDX PHARMA PLC

* JOUNCE HAS CONFIRMED THAT IT DOES NOT WISH TO SWITCH TO A CONTRACTUAL TAKEOVER OFFER

* JOUNCE'S BOARD OF DIRECTORS HAS WITHDRAWN ITS RECOMMENDATION TO PROCEED WITH REDX BUSINESS COMBINATION

* JOUNCE BELIEVES IT IS UNLIKELY THAT JOUNCE STOCKHOLDERS WOULD SUPPORT REDX BUSINESS COMBINATION

* JOUNCE HAS CONFIRMED THAT IT DOES NOT WISH TO SWITCH TO A CONTRACTUAL TAKEOVER OFFER

* JOUNCE'S DECISION WAS BASED UPON RECEIPT OF AN UNSOLICITED PROPOSAL FROM CONCENTRA BIOSCIENCES

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2324340178?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-03 14:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2324340178","market":"us","top_or_hot":-1,"title":"BRIEF-Jounce Says Termination Of Proposed Business Combination With Redx Pharma PLC","media":"Reuters","content":"<html><body><p>April 3 (Reuters) - Jounce Therapeutics Inc   :</p><p>   * TERMINATION OF PROPOSED BUSINESS COMBINATION OF JOUNCE THERAPEUTICS, INC. AND <a href=\"https://laohu8.com/S/REDX.UK\">REDX PHARMA PLC</a></p><p>   * JOUNCE HAS CONFIRMED THAT IT DOES NOT WISH TO SWITCH TO A CONTRACTUAL TAKEOVER OFFER</p><p>   * JOUNCE'S BOARD OF DIRECTORS HAS WITHDRAWN ITS RECOMMENDATION TO PROCEED WITH REDX BUSINESS COMBINATION</p><p>   * JOUNCE BELIEVES IT IS UNLIKELY THAT JOUNCE STOCKHOLDERS WOULD SUPPORT REDX BUSINESS COMBINATION</p><p>   * JOUNCE HAS CONFIRMED THAT IT DOES NOT WISH TO SWITCH TO A CONTRACTUAL TAKEOVER OFFER</p><p>   * JOUNCE'S DECISION WAS BASED UPON RECEIPT OF AN UNSOLICITED PROPOSAL FROM CONCENTRA BIOSCIENCES</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Jounce Says Termination Of Proposed Business Combination With Redx Pharma PLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Jounce Says Termination Of Proposed Business Combination With Redx Pharma PLC\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-03 14:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 3 (Reuters) - Jounce Therapeutics Inc   :   * TERMINATION OF PROPOSED BUSINESS COMBINATION OF JOUNCE THERAPEUTICS, INC. AND REDX PHARMA PLC   * JOUNCE HAS CONFIRMED THAT IT DOES NOT WISH TO ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2324340178","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2324340178","pubTimestamp":1680501943,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 3 (Reuters) - Jounce Therapeutics Inc   :   * TERMINATION OF PROPOSED BUSINESS COMBINATION OF ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PLC":"PLC"},"translate_title":"BRIEF-Jounce表示终止与Redx Pharma PLC的拟议业务合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLC":1,"JNCE":0.9},"content_text":"April 3 (Reuters) - Jounce Therapeutics Inc   :   * TERMINATION OF PROPOSED BUSINESS COMBINATION OF JOUNCE THERAPEUTICS, INC. AND REDX PHARMA PLC   * JOUNCE HAS CONFIRMED THAT IT DOES NOT WISH TO SWITCH TO A CONTRACTUAL TAKEOVER OFFER   * JOUNCE'S BOARD OF DIRECTORS HAS WITHDRAWN ITS RECOMMENDATION TO PROCEED WITH REDX BUSINESS COMBINATION   * JOUNCE BELIEVES IT IS UNLIKELY THAT JOUNCE STOCKHOLDERS WOULD SUPPORT REDX BUSINESS COMBINATION   * JOUNCE HAS CONFIRMED THAT IT DOES NOT WISH TO SWITCH TO A CONTRACTUAL TAKEOVER OFFER   * JOUNCE'S DECISION WAS BASED UPON RECEIPT OF AN UNSOLICITED PROPOSAL FROM CONCENTRA BIOSCIENCESSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2324340178"}